Jodi Caddell
Family · Midlothian, VANPI 1225588874
Payments from drug & device makers
Across 238 payments — averaging $15.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$709
- Novo Nordisk$378
- Lilly USA, LLC$370
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$219
- Amgen$186
- AstraZeneca$152
- plus $2K from 31 others
What the payments were for
- Food & beverage$3,681100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 50 | $709 |
| Novo Nordisk | 27 | $378 |
| Lilly USA, LLC | 27 | $370 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $219 |
| Amgen | 13 | $186 |
| AstraZeneca | 10 | $152 |
| Teva Pharmaceuticals USA, Inc. | 8 | $140 |
| Pfizer | 9 | $138 |
| Daiichi Sankyo Inc. | 7 | $137 |
| Biohaven Pharmaceuticals, Inc. | 8 | $133 |
| Otsuka America Pharmaceutical, Inc. | 6 | $120 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $100 |
| Boehringer Ingelheim | 6 | $84 |
| Abbott | 4 | $79 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $69 |
| Merck | 3 | $58 |
| Amneal Pharmaceuticals LLC | 4 | $57 |
| GSK | 3 | $52 |
| Amarin Pharma, Inc. | 2 | $42 |
| Nestle Healthcare Nutrition Inc. | 3 | $42 |
| Exact Sciences | 2 | $41 |
| Dexcom, Inc. | 2 | $41 |
| Actelion Pharmaceuticals US, Inc. | 2 | $38 |
| Novartis | 2 | $38 |
| Idorsia Pharmaceuticals US Inc | 2 | $35 |
| Seqirus USA Inc | 2 | $31 |
| Bayer | 2 | $29 |
| Lifescan, Inc. | 1 | $22 |
| Sanofi Pasteur Inc. | 1 | $21 |
| Mannkind Corporation | 1 | $18 |
| Gilead | 1 | $17 |
| Exeltis, USA Inc. | 1 | $16 |
| Edwards Lifesciences | 1 | $14 |
| Astellas Pharma US Inc | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Eisai Inc. | 1 | $13 |
| Genentech USA, Inc. | 2 | $13 |
How this compares
$3,681 in reported general payments places this provider in the 90th percentile of 4,332 family providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ValacyclovirValacyclovir Hcl | 12 | $285 |
| Atorvastatin Calcium | 16 | $241 |
| Losartan Potassium | 20 | $204 |
| Levothyroxine Sodium | 24 | $150 |
| Rosuvastatin Calcium | 12 | $78 |
| Amlodipine Besylate | 17 | $51 |
| Sertraline Hcl | 14 | $44 |
| Lisinopril | 13 | $34 |
| Hydrochlorothiazide | 11 | $32 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $57 | $15024 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,332 family providers in Virginia.
Other family in Midlothian
- Sean OlaughlinMidlothian$110K
- Andrea CottonVirginia Beach$696K
- Susan MooreWytheville$438K
- Ellen WermterCharlottesville$251K
- Dana StallingsFranklin$225K
- Jocelyn BrackettHerndon$199K
- Hochong Smith GillesRichmond$131K
- Adam MedlinHampton$67K
- Casey SharpDanville$63K
- Norman JacobowitzManassas$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.